{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:38:44Z","timestamp":1793252324192,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdsjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jdermsci.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T15:49:41Z","timestamp":1490111381000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria"],"prefix":"10.1016","volume":"87","author":[{"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooyoung","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Chinuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Woong","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Keol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jdermsci.2017.03.009_bib0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jdermsci.2017.03.009_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic spontaneous urticaria: etiology and pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"3","key":"10.1016\/j.jdermsci.2017.03.009_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.jdermsci.2017.03.009_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1034\/j.1398-9995.2003.00091.x","article-title":"Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy","volume":"58","author":"Baiardini","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0025","article-title":"Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria","author":"Choi","year":"2016","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2133.1997.tb14895.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O'Donnell","year":"1997","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2017.03.009_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4168\/aair.2012.4.6.326","article-title":"Treatment of chronic spontaneous urticaria","volume":"4","author":"Kaplan","year":"2012","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","article-title":"Omalizumab","volume":"61","author":"Easthope","year":"2001","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jdermsci.2017.03.009_bib0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.alit.2015.05.006","article-title":"Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy","volume":"64","author":"Odajima","year":"2015","journal-title":"Allergol. Int."},{"issue":"8","key":"10.1016\/j.jdermsci.2017.03.009_bib0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1843.2009.01633.x","article-title":"Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma","volume":"14","author":"Ohta","year":"2009","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2332\/allergolint.09-OA-0137","article-title":"One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma","volume":"59","author":"Ohta","year":"2010","journal-title":"Allergol. Int."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0065","unstructured":"Xolair Summary of Product Characteristics, https:\/\/www.medicines.org.uk\/emc\/medicine\/24912, 2017 (Accessed 08 March 2017)."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0070","unstructured":"Xolair Prescribing Information. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf, 2017 (Accessed 08 March 2017)."},{"issue":"1","key":"10.1016\/j.jdermsci.2017.03.009_bib0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.jdermsci.2017.03.009_bib0080","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jdermsci.2017.03.009_bib0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/all.12078","article-title":"Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine","volume":"68","author":"Hiragun","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0095","first-page":"134","article-title":"Analysis of the prevalence of subtypes of urticaria and angioedema","volume":"55","author":"Tanaka","year":"2006","journal-title":"Arerugi"},{"issue":"8","key":"10.1016\/j.jdermsci.2017.03.009_bib0100","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.jdermsci.2017.03.009_bib0105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2230.2010.03840.x","article-title":"Epidemiology of urticaria: a representative cross-sectional population survey","volume":"35","author":"Zuberbier","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2017.03.009_bib0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2332\/allergolint.12-RAI-0497","article-title":"Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries","volume":"61","author":"Hide","year":"2012","journal-title":"Allergol. Int."},{"issue":"121","key":"10.1016\/j.jdermsci.2017.03.009_bib0115","first-page":"1339","article-title":"JDA guidelines. Guidelines for the diagnosis and treatment of urticaria]. Nihon Hifukagakkai Zasshi","volume":"2011","author":"Hide","year":"2011","journal-title":"Jpn. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0120","series-title":"ICH Harmonised Tripartite Guidelines. Ethnic Factors in the Acceptablity of Foreign Clinical Data E5 (R1)","author":"International Conference on Harmonisation","year":"1998"},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0125","series-title":"Ich-e5","author":"PMDA","year":"1998"},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0130","series-title":"Guideline for Evaluation of Bridging Study Data","author":"Korean Food & Drug Administration","year":"2008"},{"issue":"1","key":"10.1016\/j.jdermsci.2017.03.009_bib0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/2229-3485.173781","article-title":"Interactive Voice\/Web response system in clinical research","volume":"7","author":"Ruikar","year":"2016","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0140","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329223, 2017. (Accessed 08 March 2017)."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0145","series-title":"Last Amended by the 59th WMA General Assembly","article-title":"Ethical principles for medical research involving human subjects","author":"Declaration of Helsinki","year":"2008"},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0150","series-title":"ICH Harmonised Tripartite Guidelines. Good Clinical Practice","author":"International Conference on Harmonisation","year":"2017"},{"issue":"3","key":"10.1016\/j.jdermsci.2017.03.009_bib0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2500\/aap.2012.33.3508","article-title":"Adaptation and validation of the Urticaria Patient Daily Diary for adolescents","volume":"33","author":"Mathias","year":"2012","journal-title":"Allergy Asthma Proc."},{"issue":"1","key":"10.1016\/j.jdermsci.2017.03.009_bib0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","article-title":"Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria","volume":"108","author":"Mathias","year":"2012","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jdermsci.2017.03.009_bib0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1081\/BIP-100104194","article-title":"Accounting for dropout bias using mixed-effects models","volume":"11","author":"Mallinckrodt","year":"2001","journal-title":"J. Biopharm. Stat."},{"issue":"2","key":"10.1016\/j.jdermsci.2017.03.009_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/biomet\/asn007","article-title":"Hierarchical testing of variable importance","volume":"95","author":"Meinhausen","year":"2008","journal-title":"Biometrika"},{"issue":"7","key":"10.1016\/j.jdermsci.2017.03.009_bib0185","doi-asserted-by":"crossref","first-page":"A611","DOI":"10.1016\/j.jval.2014.08.2140","article-title":"Categorical health states in chronic spontaneous urticaria (CSU) based on the weekly urticaria activity score (UAS7): are they distinct, discriminative, and reproducible?","volume":"17","author":"Stull","year":"2014","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jdermsci.2017.03.009_bib0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4168\/aair.2016.8.5.396","article-title":"Guideline of chronic urticaria beyond","volume":"8","author":"Fine","year":"2016","journal-title":"Allergy Asthma Immunol. Res."},{"issue":"4","key":"10.1016\/j.jdermsci.2017.03.009_bib0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2017.03.009_bib0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-3-36","article-title":"Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria","volume":"3","author":"Shikiar","year":"2005","journal-title":"Health Qual. Life Outcomes"},{"issue":"6","key":"10.1016\/j.jdermsci.2017.03.009_bib0205","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin. Exp. Allergy"},{"issue":"4","key":"10.1016\/j.jdermsci.2017.03.009_bib0210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jdermsci.2017.03.009_bib0215","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jdermsci.2017.03.009_bib0220","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.dmpk.2015.12.003","article-title":"Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion","volume":"31","author":"Honma","year":"2016","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181117300877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181117300877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:50:43Z","timestamp":1535953843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181117300877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0923181117300877"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2017.03.009","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}